Effects of insulin vs. glibenclamide in recently diagnosed patients with type 2 diabetes: A 4-year follow-up

Diabetes, Obesity and Metabolism

Volumn 10, Issue 5, 2008, Pages 421-429

  Alvarsson, Michael ^a   Sundkvist, G ^b,c   Lager, I ^d   Berntorp, K ^b,c   Fernqvist Forbes, E ^e   Steen, L ^f   Orn T ^g   Holberg, M A ^h   Kirksaether N ^h   Grill, V ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d CENTRAL HOSPITAL   (Sweden)

^e Visby Hospital   (Sweden)

^f Department of Medicine ^*  (Sweden)

^g BLEKINGE HOSPITAL   (Sweden)

^h NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

Beta cell protection; Diabetes mellitus; Glibenclamide; Insulin; Insulin secretion

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLIBENCLAMIDE; GLUCAGON; GLUCOSE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOPHANE INSULIN; PROINSULIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC RETINOPATHY; DISEASE DURATION; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; HYPOGLYCEMIA; MALE; METABOLIC REGULATION; MONOTHERAPY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET CELL FUNCTION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SHORT COURSE THERAPY; SHORT FORM 36; STATISTICAL SIGNIFICANCE; SWEDEN; WEIGHT GAIN;

EID: 42149083835     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2007.00719.x     Document Type: Article

References (21)

1. U.K. Prospective Diabetes Study Group. UK prospective diabetes study 16. Overview of 6 years'therapy of type II diabetes: A progressive disease. Diabetes 1995; 44: 1249-1258.
2. Grill V, Bjorklund A. Overstimulation and beta-cell function. Diabetes 2001; 50 (Suppl. 1): S122-S124.
3. Buchanan TA. Pancreatic beta-cell loss and preservation in type 2 diabetes. Clin Ther 2003; 25 (Suppl. B): B32-B46.
4. Fridlyand LE, Philipson LH. Does the glucose-dependent insulin secretion mechanism itself cause oxidative stress in pancreatic beta-cells? Diabetes 2004; 53: 1942-1948.
5. Alvarsson M, Sundkvist G, Lager I et al. Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients. Diabetes Care 2003; 26: 2231-2237.
6. Jeppsson JO, Jerntorp P, Almer LO, Persson R, Ekberg G, Sundkvist G. Capillary blood on filter paper for determination of HbA1c by ion exchange chromatography. Diabetes Care 1996; 19: 142-145.
7. Henricsson M, Nystrom L, Blohme G et al. The incidence of retinopathy 10 years after diagnosis in young adult people with diabetes: Results from the nationwide population-based Diabetes Incidence Study in Sweden (DISS). Diabetes Care 2003; 26: 349-354.
8. Ware J Jr, Sherbourne C. The MOS 36-item Short-Form Health Survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 473-483.
9. Olsson ML, Sundkvist G, Lernmark A. Prolonged incubation in the two-colour immunofluorescence test increases the prevalence and titres of islet cell antibodies in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1987; 30: 327-332.
10. Borg H, Fernlund P, Sundkvist G. Protein tyrosine phosphatase-like protein IA2-antibodies plus glutamic acid decarboxylase 65 antibodies (GADA) indicates autoimmunity as frequently as islet cell antibodies assay in children with recently diagnosed diabetes mellitus. Clin Chem 1997; 43: 2358-2363.
11. Borg H, Fernlund P, Sundkvist G. Measurement of antibodies against glutamic acid decarboxylase 65 (GADA): Two new 125I assays compared with [35S]GAD 65-ligand binding assay. Clin Chem 1997; 43: 779-785.
12. Jeppsson JO, Jerntorp P, Sundkvist G, Englund H, Nylund V. Measurement of hemoglobin A1c by a new liquid-chromatographic assay: Methodology, clinical utility, and relation to glucose tolerance evaluated. Clin Chem 1986; 32: 1867-1872.
13. Clauson P, Linnarsson R, Gottsater A, Sundkvist G, Grill V. Relationships between diabetes duration, metabolic control and beta-cell function in a representative population of type 2 diabetic patients in Sweden. Diabet Med 1994; 11: 794-801.
14. Bjorklund A, Grill V. Enhancing effects of long-term elevated glucose and palmitate on stored and secreted proinsulin-to-insulin ratios in human pancreatic islets. Diabetes 1999; 48: 1409-1414.
15. Bolinder J, Fernlund P, Borg H et al. Hyperproinsulinemia segregates young adult patients with newly diagnosed autoimmune (type 1) and non-autoimmune (type 2) diabetes. Scand J Clin Lab Invest 2005; 65: 585-594.
16. Maedler K, Carr RD, Bosco D, Zuellig RA, Berney T, Donath MY. Sulfonylurea induced beta-cell apoptosis in cultured human islets. J Clin Endocrinol Metab 2005; 90: 501-506.
17. Melander A, Donnelly R, Rydberg T. Is there a concentration-effect relationship for sulphonylureas? Clin Pharmacokinet 1998; 34: 181-188.
18. Wright A, Burden AC, Paisey RB, Cull CA, Holman RR. Sulfonylurea inadequacy: Efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002; 25: 330-336.
19. Makimattila S, Nikkila K, Yki-Jarvinen H. Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus. Diabetologia 1999; 42: 406-412.
20. Yki-Jarvinen H. Combination therapies with insulin in type 2 diabetes. Diabetes Care 2001; 24: 758-767.
21. Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). UK Prospective Diabetes Study Group. Diabetes Care 1999; 22: 1125-1136.